| Members |
targetComponentId |
| Melanotic neuroectodermal tumor of infancy |
Melanotic neuroectodermal tumor of infancy |
| Melasian type |
Melasian type |
| Memantine 2mg/mL oral solution (product) |
Memantine hydrochloride 2 mg/mL oral solution |
| Membrane metallo-endopeptidase (substance) |
Lymphocyte antigen CD10 (substance) |
| Memory disturbance (& amnesia (& symptom)) |
trouble de la mémoire |
| Memory impairment |
trouble de la mémoire |
| Meningeal neoplasm, uncertain whether benign or malignant (morphologic abnormality) |
Meningioma of uncertain behavior (morphologic abnormality) |
| Meningioma, benign, no International Classification of Diseases for Oncology subtype (morphologic abnormality) |
Benign meningioma |
| effet indésirable du vaccin polysaccharidique contre le méningocoque |
effet indésirable du vaccin contre le méningocoque |
| Menstrual molimen |
Premenstrual tension syndrome |
| Mental disorder - unspecified whether during pregnancy or the puerperium |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental disorder during pregnancy, childbirth or the puerperium NOS |
Mental disorders during pregnancy, childbirth and the puerperium |
| Mental handicap (finding) |
Intellectual disability |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap (specialty) |
Intellectual disability specialty |
| Mental handicap psychiatry department |
Intellectual disability psychiatry department (environment) |
| service de psychiatrie en déficience mentale |
Intellectual disability psychiatry service |
| Mental health crisis plan (qualifier value) |
Mental health crisis plan |
| Mental health personal health plan (qualifier value) |
Mental health personal health plan |
| Mental retardation |
Intellectual disability |
| Mental retardation screening |
Intellectual disability screening |
| Menthol 35.55mg inhalant capsule (product) |
Product containing only menthol in pulmonary dose form (medicinal product form) |
| Mepacrine hydrochloride 100mg tablet (product) |
Product containing precisely mepacrine hydrochloride 100 milligram/1 each conventional release oral tablet (clinical drug) |
| Meperidine hydrochloride 100mg/mL injection solution ampule (product) |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/5mL syrup (product) |
Product containing precisely pethidine hydrochloride 10 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Meperidine hydrochloride 50mg/mL injection solution ampule (product) |
Product containing only pethidine in parenteral dose form (medicinal product form) |
| Meperidine hydrochloride 50mg/promethazine hydrochloride 50mg injection solution vial (product) |
Product containing only pethidine and promethazine (medicinal product) |
| Mepivacaine hydrochloride 3%/levonordefrin 1:20,000 injection solution vial (product) |
Product containing precisely corbadrine 50 microgram/1 milliliter and mepivacaine hydrochloride 30 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mepivacaine hydrochloride 30mg/sodium chloride 3mg injection solution vial (product) |
Mepivacaine only product |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge (product) |
Product containing precisely epinephrine 10 microgram/1 milliliter and mepivacaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mepivacaine hydrochloride+epinephrine 2%/1:100,000 cartridge (product) |
Product containing precisely epinephrine 10 microgram/1 milliliter and mepivacaine hydrochloride 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 100mg/1mL injection (product) |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 100mg/mL injection solution 1mL ampule (product) |
Product containing precisely meptazinol (as meptazinol hydrochloride) 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Meptazinol 200mg tablet (product) |
Meptazinol (as meptazinol hydrochloride) 200 mg oral tablet |
| Mercurophylline injection |
Mercurophylline |
| Merselene patch |
Polyester mesh (physical object) |
| Mesalamine 250mg capsule (product) |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg m/r capsule (product) |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 250mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg m/r capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalamine 375mg prolonged-release oral capsule |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 1g/100mL retention enema (product) |
Mesalamine only product in rectal dose form |
| Mesalazine 1g/100mL retention enema (product) |
Mesalamine only product in rectal dose form |
| Mesalazine 2g/59mL enema (product) |
Mesalamine only product in rectal dose form |
| Mesalazine 500mg/sachet gastro-resistant and prolonged-release oral granules |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine 500mg/sachet m/r granules (product) |
Product containing only mesalazine in oral dose form (medicinal product form) |
| Mesalazine duplicate deleted (product) |
mésalazine |
| Mesenteric venous thrombosis |
Thrombosis of mesenteric vein |
| Mesio-occlusion (disorder) |
Mesio-occlusion of teeth |
| Mesonephric tumor |
Wolffian tumor of uncertain behavior (morphologic abnormality) |
| Mesoridazine besylate 10mg/mL injection solution ampule (product) |
Product containing precisely mesoridazine 10 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesoridazine besylate 25mg/mL injection solution ampule (product) |
Product containing precisely mesoridazine 25 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Mesothelioma, biphasic, benign (morphologic abnormality) |
Mesothelioma, benign |
| Metabolic disease, NEC (disorder) |
trouble métabolique |
| Metabolic marker (substance) |
Inborn errors of metabolism marker |
| Metaiodobenzylguanidine[123I] 74MBq/mL injection (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[123I] 74MBq/mL powder for injection solution vial (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL injection (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I] 37MBq/mL powder for injection solution vial (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]370MBq/mL injection (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]37MBq/mL diagnostic injection (product) |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metaiodobenzylguanidine[131I]9.25MBq/mL diagnostic injection |
Iobenguane (131-I)-containing product in parenteral dose form |
| Metallocarboxypeptidase |
Metallocarboxypeptidase |
| Metalloproteinase |
Metalloproteinase |
| Metaproterenol 20mg tablet (product) |
Product containing precisely orciprenaline sulfate 20 milligram/1 each conventional release oral tablet (clinical drug) |
| Metaproterenol sulfate 0.65mg/inh aerosol (product) |
Product containing only orciprenaline in pulmonary dose form (medicinal product form) |
| Metaproterenol sulfate 15mg/mL aerosol (product) |
Product containing precisely orciprenaline sulfate 15 milligram/1 milliliter conventional release solution for inhalation (clinical drug) |
| Metastasis stage M1a (finding) |
American Joint Committee on Cancer cM1a (qualifier value) |
| Metastasis stage M1b (finding) |
American Joint Committee on Cancer cM1b (qualifier value) |
| Metastasis stage M1c (finding) |
cM1c |
| Metastasis stage M2 (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage M3 (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage M4 (finding) |
American Joint Committee on Cancer cM1 (qualifier value) |
| Metastasis stage pM1 (finding) |
American Joint Committee on Cancer pM1 (qualifier value) |
| Metatarsal phalangeal joint flap |
Flap (substance) |
| Methacholine 2.5% eye drops |
Product containing precisely methacholine 25 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Methacholine chloride 100mg powder (product) |
Product containing only methacholine (medicinal product) |
| Methadone 10mg/5mL mixture (product) |
Product containing precisely methadone hydrochloride 2 milligram/1 milliliter conventional release oral solution (clinical drug) |
| Methadone hydrochloride 40mg dispersible tablet (product) |
Product containing precisely methadone hydrochloride 40 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
| Methamphetamine hydrochloride 10mg m/r tablet (product) |
Methamphetamine only product in oral dose form |
| Methamphetamine hydrochloride 10mg prolonged-release oral tablet |
Methamphetamine only product in oral dose form |
| Methamphetamine hydrochloride 15mg m/r tablet (product) |
Methamphetamine only product in oral dose form |
| Methamphetamine hydrochloride 15mg prolonged-release oral tablet |
Methamphetamine only product in oral dose form |
| Methamphetamine hydrochloride 5mg m/r tablet |
Methamphetamine only product in oral dose form |
| Methamphetamine hydrochloride 5mg prolonged-release oral tablet (product) |
Methamphetamine only product in oral dose form |
| Methohexital sodium 5g powder for injection solution vial (product) |
Product containing only methohexital (medicinal product) |
| Methoxsalen 20mcg/mL injection solution 10mL vial (product) |
Methoxsalen 20 microgram/mL solution for injection |
| Methyl aminolevulinate 168mg/g topical cream (product) |
Methyl aminolevulinate (as methyl aminolevulinate hydrochloride) 168 mg/g cutaneous cream |
| Methyl methacrylate embolism (morphologic abnormality) |
Foreign body embolus |
| Methyl parathion (substance) |
Hexaethyl tetraphosphate |
| Methylcellulose 1% eye drops (product) |
Methylcellulose 10 mg/mL eye solution |
| Methylene blue 1% injection solution vial (product) |
Product containing only methylthioninium chloride in parenteral dose form (medicinal product form) |
| Methylene blue 65mg tablet (substance) |
Methylene blue 65 mg oral tablet |
| Methylenedioxymethamphetamine dependence with current use (disorder) |
Methylenedioxymethamphetamine dependence |
| Methylobacterium animovorans |
Methylorubrum aminovorans (organisme) |
| Methylobacterium lusitanum (organism) |
Methylorubrum rhodesianum (organisme) |
| Methylphenidate 10mg chewable tablet (product) |
Methylphenidate hydrochloride 10 mg chewable tablet |
| Methylphenidate 2.5mg chewable tablet (product) |
Product containing precisely methylphenidate hydrochloride 2.5 milligram/1 each conventional release chewable tablet (clinical drug) |
| Methylphenidate 5mg chewable tablet (product) |
Methylphenidate hydrochloride 5 mg chewable tablet |
| Methylphenidate hydrochloride 10mg m/r tablet (product) |
Product containing only methylphenidate in oral dose form (medicinal product form) |
| Methylphenidate hydrochloride 10mg prolonged-release oral tablet |
Product containing only methylphenidate in oral dose form (medicinal product form) |
FHIR